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Abstract
Background: Although genetic studies suggest an overlap in risk alleles across the major psychiatric disorders, disease 
signatures reflecting overlapping symptoms have not been found. Profiling studies have identified candidate protein markers 
associated with specific disorders of the psychoaffective spectrum, but this has always been done in a selective fashion 
without accounting for the entire proteome composition of the system under investigation.
Methods: Employing an orthogonal system-based proteomic enrichment approach based on label-free liquid chromatography 
mass spectrometry, we analyzed anterior prefrontal human post-mortem brain tissue of patients affected by schizophrenia 
(n  =  23), bipolar disorder (n  =  23), major depressive disorder with (n  =  12) and without psychotic features (n  =  11), and 
healthy controls (n = 23). Labeled selected reaction monitoring (SRM) was used to validate these findings on a pathway level. 
Independent in silico analyses of biological annotations revealed common pathways across the diseases, associated with 
presynaptic glutamatergic neurotransmission and energy metabolism. We validated the proteomic findings using SRM and 
confirmed that there were no effects of post-mortem confounders.
Results: Schizophrenia and affective psychosis were linked to a hypoglutamatergic state and hypofunction of energy 
metabolism, while bipolar disorder and major depressive disorder were linked to a hyperglutamatergic state and hyperfunction 
of energy metabolism.
Conclusions: These findings support recent investigations, which have focused on the therapeutic potential of glutamatergic 
modulation in psychotic and affective disorders. We suggest a disease model in which disturbances of the glutamatergic 
system and ensuing adaptations of neuronal energy metabolism are linked to distinct psychiatric symptom dimensions, 
delivering novel evidence for targeted treatment approaches.
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Introduction
The etiology of the major psychiatric disorders still remains elu-
sive. At the forefront of psychiatric research have been extensive 
genetic studies (Levinson, 2006; Owen et al., 2010; Craddock and 
Sklar, 2013), which have often generated contradictory findings. 
Consequently, this has impeded the development of a coherent 
disease model. Currently, schizophrenia (SZ), bipolar disorder (BD), 
and major depressive disorder are defined by symptom patterns 
and, to a lesser degree, disease course. However, some core symp-
toms such as psychosis, affective disturbances, and cognitive 
dysfunctions overlap between disorder categories. The question 
arises whether there are proteomic features shared between these 
complex disorders and if they converge onto the same pathways.
The largest genome-wide association (GWA) study of the 
major psychiatric disorders to date has identified a number 
of shared risk loci, mainly located within genes associated 
with calcium channel signaling (Smoller et al., 2013). However, 
it remains to be determined how genetic changes affect the 
expression and function of the encoded proteins and the bio-
logical system in question (Smoller et al., 2013).
Genetic analyses of patients presenting with either psy-
chotic or mood disorders have suggested a greater overlap of 
risk loci between SZ and BD compared to BD and depression 
(Purcell et  al., 2009; Williams et  al., 2011; Smoller et  al., 2013). 
However, twin and GWA studies imply shared susceptibility fac-
tors for BD and depression (Green et al., 2010; McMahon et al., 
2010). These observations have promoted a dimensional under-
standing of psychotic, manic, and depressive symptoms (van 
Os and Kapur, 2009). Familial co-segregation of schizoaffective 
disorder, SZ, BD, and major depressive disorder (Tsuang and 
Faraone, 1990; Craddock et  al., 2009; Lichtenstein et  al., 2009), 
and shared susceptibility markers across diagnostic hierarchy 
boundaries (Cardno et al., 2002) argue for a critical review of the 
current psychiatric nosology. Given the polygenic etiology of the 
major psychiatric disorders, we investigated whether there are 
common changes in biological pathways and whether diagno-
ses with overlapping symptom dimensions also share similar 
pathophysiologies, employing an orthogonal system-based pro-
teomic approach.
As the proteome represents the transcribed and translated 
genetic information following modifications at the epigenetic 
and mRNA levels, it has been suggested that proteomics is closer 
to reflecting the pathophysiological disease end point than 
genomics and transcriptomics (Bayes and Grant, 2009). However, 
the focus of molecular psychiatry research has predominantly 
remained on single disorders and sets of individual proteins 
rather than multiple disorders and protein networks. Such an 
approach runs the risk of missing effects at the system level. 
Findings in psychiatric proteomics have mostly been analyzed 
on the basis of an individual protein being involved in a given 
pathway (English et al., 2011), rather than testing for significant 
overrepresentation of dysregulated proteins sharing common 
pathways within the detected proteome (Wesseling et al., 2014).
Thus, in order to investigate psychotic and affective dimen-
sions, we conducted a non-hypothesis–driven proteomic screen 
in post-mortem brain tissue (Brodman Area 10 [BA10]) from a 
total of 23 SZ, 23 BD, and 23 major depressive disorder patients 
and 23 controls. Major depressive disorder patients were further 
divided into subgroups with and without psychosis. Previous 
work has implicated the anterior prefrontal cortex in the inte-
gration and coordination of information processing and transfer 
in multi-operational cognitive tasks (Ramnani and Owen, 2004). 
This mediator position made BA10 a primary target in affective 
and psychotic disorders characterized by impairments in execu-
tive functioning and socio-emotional cognition.
The only study investigating BA10 protein changes in neu-
ropsychiatric disorders used a conventional 2D-gel based tech-
nique (Johnston-Wilson et  al., 2000). However, due to some 
limitations (Lilley, 2003), this method was superseded by highly 
sensitive mass spectrometry methods (e.g. liquid chromatog-
raphy coupled tandem mass spectrometry [LC-MS E]) allowing 
quantitative protein profiling (Bayes and Grant, 2009). To over-
come the bottleneck of validation in such screening studies, 
recent advances in mass spectrometry have led to the devel-
opment of selected reaction monitoring (SRM) as a targeted 
proteomic approach to quantify levels of putative biomarkers—
without the need of antibody-based methods like ELISAs and 
immunoblotting—in a highly accurate and quantitative man-
ner (Picotti and Aebersold, 2012). To our knowledge, this is the 
first proteomic investigation which has attempted to integrate 
the spectrum of major psychiatric disorders in one single study, 
comprising 92 well-matched patient and control samples ana-
lyzed by label-free LC-MSE proteomic profiling, combined with 
protein-set enrichment analysis and SRM validation.
Methods
Clinical Samples
A total of 92 post-mortem anterior prefrontal cortex (BA10) 
brain samples were obtained from the Stanley Medical Research 
Institute (Torrey et al., 2000). Samples were derived from 23 SZ 
patients, 23 BD patients, 12 major depressive disorder patients 
without psychotic symptoms (MDD), 11 major depressive disor-
der patients with psychotic symptoms (MDD-P), and 23 control 
(CT) subjects. Tissue was collected post-mortem from patients 
and controls with full informed consent obtained from a first-
degree relative in compliance with the Declaration of Helsinki; 
consent was obtained by questionnaires conducted over the 
phone and signed by two witnesses. The patient samples were 
matched with control samples based upon age at death, post-
mortem interval, and brain pH (t-test). There were no significant 
differences in brain side, gender or secondary axis diagno-
sis of alcohol abuse/dependency and drug abuse/dependency 
between patients and controls (Fisher’s exact test). Samples 
contained equal amounts of grey and white matter, as deter-
mined by neuroanatomical analyses. A summary of the demo-
graphic details and p values is shown in Supplementary Table 
S1. Additional information is provided in Supplementary Table 
S2. Tissues were sectioned (25 μm) using a Leica Cryostat (Milton 
Keynes) and stored at -80 C until use.
Sample Preparation
Approximately 50 mg of tissue slices per sample were used in 
this study. Total lysis sample preparation was performed as previ-
ously described (Ernst et  al., 2012). Briefly, tissue samples were 
added to a fractionation buffer containing 7 M urea, 2 M thiourea, 
4% CHAPS, 2% ASB14, and 70 mM DTT at a 5:1 (v/w) ratio. After 
sonication and vortexing for 30 min, lysates were centrifuged for 
1 min at 5000 rpm to remove residual cell debris and protein con-
centrations of the supernatant were determined using a Bradford 
assay (Bio-Rad). Based on the lysates, two randomized, blinded, 
independent sample preparations (for all 92 samples) were per-
formed for LC-MSE and SRM to avoid bias in sample preparations. 
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Protein (approx. 100 μg) was precipitated using acetone. For qual-
ity control purposes, a pool of all lysates was split into ten ali-
quots and prepared in parallel with the samples. After dissolving 
the precipitate in 50 mM ammonium bicarbonate, protein con-
centrations were determined in quadruplicate. Reduction of pro-
tein sulfhydryl groups was performed with 5 mM DTT at 60°C for 
30 min and alkylation was carried out using 10 mM iodacetamide 
and incubating in the dark at 37°C for 30 min. Digestion of the 
proteins was conducted using trypsin at a 1:50 (w/w) ratio for 17 h 
at 37°C, and reactions were stopped by addition of 8.8 M HCl in 
a 1:60 (v/v) ratio. All sample aliquots were stored at -80°C until 
analysis.
Label-Free LC−MSE Analysis of Brain Tissue
Brain tissue samples were analyzed individually in technical 
duplicates using splitless nano-ultra-performance liquid chro-
matography (10 kpsi nanoAcquity; Waters Corporation), coupled 
online through a New Objective nanoESI emitter (7 cm length, 
10-mm tip; New Objective) to a Waters Q-TOF Premier mass 
spectrometer. Data were acquired in expression mode (MSE) 
and the total continuous run time was 31 days. The procedure, 
quality assessment and data processing were performed as 
described previously (Ernst et al., 2012). Data were acquired in 
MSE positive V mode. The cycle time per scan was 1.25 s. During 
low-energy scans, the collision energy was set to 5eV and during 
high-energy scans this was ramped from 17eV to 40eV. LC-MSE 
data were processed using the ProteinLynx Global Server v.2.5. 
(Waters Corporation), and Rosetta Elucidator v.3.3 (Rosetta 
Biosoftware) was used for time and mass/charge alignment of 
mass spectrometry data. The Swiss-Prot human reference pro-
teome (Uniprot release, March 2013; 20 252 entries) was used 
for protein identification searches. To control the false discovery 
rate (FDR), data were searched against a decoy database, which 
was the randomized version of the database mentioned above 
to conserve amino acid frequencies. The FDR was set at the 
default maximum rate of 4%, as applied before (Lu et al., 2007; 
Krishnamurthy et al., 2011; Ralhan et al., 2011; Yang et al., 2011). 
The search parameters were: (1) enzyme  =  trypsin, (2) fixed 
modification = carbamidomethylation of cysteines, (3) variable 
modifications = oxidation of methionine and phosphorylation at 
serine, threonine, or tyrosine residues, (4) initial mass accuracy 
tolerances = 10 ppm for precursor ions and 20 ppm for product 
ions, and (5) one missed cleavage allowed. In addition, the fol-
lowing criteria were used for protein identification: (1) ≥ 3 frag-
ment ions per peptide, (2) ≥ 7 fragment ions per protein, and (3) 
≥ 1 peptide per protein. Raw data and ProteinLynx Global Server 
search results were imported into the Rosetta Elucidator soft-
ware (build 3.3.0.1.SP3.19, Rosetta Biosoftware). Elucidator per-
formed the retention time alignment and feature identification 
and extraction for all samples using the Rosetta PeakTeller algo-
rithm. Dynamic background subtraction, smoothing in reten-
tion time and m/z dimensions and isotopic regions creation for 
peak-matching across all runs were calculated using an reten-
tion time correction of 4 min at the maximum. A single data file 
was randomly chosen as the master, and all other sample files 
were aligned to the master in form of a dynamic retention time 
shift. This procedure allowed the improved identification of pep-
tides and proteins in each sample by taking the available data 
of all samples into account. Features were normalized based 
on total ion current to account for potential differences in pro-
tein loading and peptide ionization. Only features detected in 
both replicates and in >80% of samples were included in fur-
ther analyses. Feature intensities were summed to generate 
peptide intensities, which were used for statistical analysis. 
Protein abundance changes for the five comparisons (SZ/CT, BD/
CT, MDD/CT, MDD-P/CT, MDD-P/MDD) were determined using 
the MSstats package (Clough et al., 2012) based on linear mixed-
effects models under defaults settings, following log2 transfor-
mation, and exclusion of intensity values deviating more than 
three standard deviations from the mean of each group. The p 
values were adjusted to control the FDR at a cut-off of 0.05 fol-
lowing the Benjamini Hochberg procedure (Chang et al., 2012).
Protein Set Enrichment Analysis
Protein set enrichment analysis was performed as described pre-
viously (Pan et al., 2009; Zhang et al., 2011). Briefly, for each disor-
der comparison, significantly-changed proteins were partitioned 
into six bins, according to fold change (FC): FC < 1.0; FC < -1.1; 
1.1 < FC <1; 1.0 < FC < 1.1; FC > 1.1; FC > 1.0. The R-package data-
base org.Hs.eg.db version 2.8.0 (17 959 entries) was used for gene 
ontology (GO) term annotation based on Entrez gene identifiers. 
Significant overrepresentation of an annotated GO term per bin 
was determined by the GOstats package (Falcon and Gentleman, 
2007). For each bin, p values for the GO categories (Ashburner 
et  al., 2000) of biological pathway (BP) and cellular compart-
ment (CC) were calculated by a conditional hypergeometric test 
using the entire detected proteome as a background. These tests 
accounted for the hierarchical structure of the GO terms by first 
testing the child terms of any given GO category and filtering 
significantly-enriched proteins prior to analysis of the parents 
terms, as described previously (Alexa et al., 2006). This prevented 
the identification of directly-related GO terms with a consider-
able overlap of assigned proteins. GO terms with no significant 
enrichment in any bin (p > 0.05) and GO terms with less than two 
annotated proteins were removed. The remaining p values greater 
than 0.05 were replaced by a conservative p value of 1. P values 
were replaced by their negative logarithm to the base of ten and 
then converted to z-scores within their proteomic comparison 
for every remaining GO term. Finally, all significantly-enriched 
GO term associations were aligned across all five proteomic com-
parisons and arranged by one-way hierarchical clustering using 
Euclidean distance as distance function and the Average Linkage 
Clustering method available in the software Genesis (Sturn et al., 
2002). The same enrichment analysis was repeated using Kyoto 
Encyclopedia of Genes and Genomes (KEGG) pathway annotation 
(5 871 entries) in order to provide an independent in silico valida-
tion of our findings. Only significantly-enriched terms appearing 
in at least 3 disorder comparisons were considered to represent 
overlapping features across the psychoaffective spectrum (fur-
ther data available upon request).
SRM Mass Spectrometry
Level alterations of proteins belonging to candidate path-
ways identified by label-free LC-MSE profiling were validated 
using targeted SRM mass spectrometry on a Xevo TQ-S mass 
spectrometer (Waters Corporation) coupled online through a 
New Objective nanoESI emitter (7 cm length, 10 mm tip; New 
Objective) to a nanoAcquity nano-ultra-performance liquid 
chromatography system (Waters Corporation). The system was 
comprised of a C18 trapping column (180 um x 20 mm, 5 μm par-
ticle size) and a C18 BEH nano-column (75 um x 200 mm, 1.7 mm 
particle size). The separation buffers were 0.1% formic acid and 
0.1% formic acid in acetonitrile. For separation of peptides, the 
following 48 min gradient was applied: 97/3% (A/B) to 60/40% in 
30 min; 60/40% to 15/85% in 2 min; 5 min at 15/85%; returning to 
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the initial condition in 1 min. The flow rate was 0.3 µL/min with 
column temperature at 35°C.
SRM assays were developed following a general high-
throughput strategy. Initially, up to 12 unique peptides rang-
ing from 6 to 20 amino acids in length, containing tryptic 
ends and no missed cleavages, were chosen for the selected 
proteins. All peptides containing amino acids prone to modi-
fications (e.g., Met, Trp, Asn, and Gln), potential ragged ends, 
or lysine/arginine followed by proline or bearing the NXT/NXS 
glycosylation motif were generally avoided and only selected 
when no other options were available (Lange et  al., 2008). 
Peptides were checked by Protein BLAST (http://blast.ncbi.nlm.
nih.gov/Blast.cgi) searches to ensure uniqueness. For method 
refinement, up to 12 transitions per peptide were tested in 
SRM mode. Transitions were calculated using Skyline version 
1.2.0.3425 (MacLean et  al., 2010) and corresponded to singly 
charged y-ions from doubly- or triply-charged precursor ions 
in the range of 350–1250 Da. Transitions were selected based 
on prediction, discovery proteomics data, and spectral data 
availability through the Human NIST spectral libraries (Farrah 
et al., 2011). Method refinement was performed on quality con-
trol samples. For the final SRM assays, the 2–3 peptides with 
the maximal intensities and highest spectral library similarity 
(dotp > 0.9) were selected. A further development step of ana-
lyzing heavy-label spiked QC samples in scheduled SRM mode 
was used to confirm identity via co-elution, extract the optimal 
fragment ions for SRM analysis, obtain accurate peptide reten-
tion times, and optimize collision energy and cone voltage for 
the quantification run applying Skyline software (MacCoss Lab 
Software; MacLean et al., 2010). Heavy-labeled forms of these 
selected peptides (spiketides L) were chemically synthesized 
via SPOT synthesis (JPT Peptide Technologies GmbH). The final 
transitions, collision energy, and retention time windows used 
for each peptide can be found in the Supplementary Materials 
(Supplementary Table S3A).
Quantitative SRM measurements comparing patients and 
controls were performed in scheduled SRM acquisition mode, 
using the optimized parameters defined during the assay refine-
ment. For each target peptide, a heavy isotope-labeled internal 
standard (JPT Peptide Technologies GmbH) was spiked in the 
peptide mixture for accurate quantification and identification. 
All SRM functions had a 2 min window of the predicted reten-
tion time and scan times were 20 ms, which ensured a dwell 
time of over 5 ms per transition. For each peptide, at least three 
transitions were monitored for the heavy and light versions. 
Samples were randomized and run in blocked triplicates (Oberg 
and Vitek, 2009). Blanks and quality control peptide injections 
(alcohol dehydrogenase; Supplementary Table S3B) were run 
alternately after every biological replicate. Resulting SRM data 
were analyzed using Skyline and protein significance analysis 
was performed using SRMstats (Chang et al., 2012). For the first 
stage, data pre-processing was performed by transforming all 
transition intensities into log2-values. Then a constant normali-
zation was conducted based on reference transitions for all pro-
teins, which equalized the median peak intensities of reference 
transitions from all proteins across all runs and adjusted the 
bias to both reference and endogenous signals. Protein-level 
quantification and testing for differential abundance among 
patient and control groups were performed using the linear 
mixed-effects model implemented in SRMstats. Each protein 
was tested for abundance differences between patients and 
healthy controls. The p values were adjusted to control the FDR 
at a cut-off of 0.05 following the Benjamini Hochberg procedure 
(Chang et al., 2012).
Results
Label-Free LC-MSE Proteomic Analysis of Post-
Mortem Anterior Prefrontal Cortex (BA10)
Proteomic analysis identified a total of 1 310 unique quantifi-
able proteins, based on 22 629 unique peptides, across all brain 
samples. Based on linear modelling, we found that 241 proteins 
(54 proteins ≥ 2 unique peptides) were differentially expressed 
in SZ patients, 664 proteins (368 proteins ≥ 2 unique peptides) 
in BD, 524 proteins (274 proteins ≥ 2 unique peptides) in MDD, 
and 224 proteins (44 proteins ≥ 2 unique peptides) in MDD-P, in 
comparison to CT individuals. In order to identify characteris-
tic changes associated with psychotic features in affective dis-
orders, we compared MDD-P to MDD and found 437 proteins 
(193 proteins ≥ 2 unique peptides) significantly differentially 
expressed. Characteristic expression profiles for each com-
parison are shown in Figure 1A–E. Based on similarities in the 
fold change direction (e.g. BD and MDD showed a tendency for 
positive fold changes) and to identify shared significant protein 
alteration patterns across disease entities, we cross-compared 
the findings using linear correlation (Figure 1F; correlation plots 
can be found in Supplementary Figure S1A–J). This enabled us 
to detect disease-specific and overlapping disease signatures 
at the protein level (Supplementary Table S4; Supplementary 
Figure S2). As expected, protein changes reflecting affective 
psychosis (MDD-P/MDD) overlapped with markers of MDD with 
psychotic features (MDD-P/CT), although no significant cor-
relation between MDD-P/CT and MDD/CT was found. Proteins 
significantly changed in the MDD-P/MDD comparison showed 
opposite directional change in BD/CT, MDD/CT and SZ/CT. BD/
CT and SZ/CT did not show significantly overlapping protein 
changes, yet biomarker patterns for both disorders were posi-
tively correlated to changes identified in MDD/CT (Figure 1F).
Functional Annotation Enrichment Analysis and 
SRM Pathway Validation
In an attempt to investigate functional implications of the 
identified overlapping changes in expression patterns, we per-
formed protein-set enrichment analysis based on GO terms 
for each disorder, using the total of significantly changed pro-
teins regardless of the magnitude of change. We assumed that 
similar pathways can be affected by distinct underlying prot-
eomic signatures and that slight variation in the expression 
of multiple proteins may result in significant pathway altera-
tions. Based on the fold-change distribution of the significant 
protein-abundance changes, we analyzed six different bins for 
overrepresentation of GO terms reflecting BP and CC, as deter-
mined by hypergeometric testing (Figure 2). The highest anno-
tation overlap of biological pathways was found between the 
comparisons of BD/CT, MDD/CT, and MDD-P/MDD. In the cellu-
lar compartment analysis the highest annotation overlap was 
found between SZ/CT, BD/CT, and MDD-P/MDD. In order to inde-
pendently validate our in silico findings, we performed the same 
analysis with KEGG pathway annotation. Two major points of 
overlap were identified between both analyses. Firstly, annota-
tions related to glutamate, represented in the GO BP analysis 
by glutamate catabolism and glutamate secretion, in the GO CC 
analysis by clathrin-sculpted glutamate transport vesicle mem-
brane, and in the KEGG pathway analysis by alanine, aspartate, 
and glutamate metabolism. Secondly, annotations related to 
energy metabolism, represented in the GO BP analysis by respir-
atory electron transport chain, gluconeogenesis, carbohydrate 
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catabolism, glycolysis, lipid catabolism, and ATP synthesis, and 
in the KEGG pathway analysis by oxidative phosphorylation and 
metabolic pathways.
Based upon the overlap between the enrichment analyses 
described above, we selected 10 proteins for the 5 biological 
pathways (2 proteins/pathway) for SRM validation, particularly 
focusing on presynaptic glutamatergic neurotransmission and 
energy metabolism (Figure 3). Additionally, we decided to evalu-
ate whether we can confirm the significant over- or under-repre-
sentation of certain pathways by including proteins not detected 
in the initial LC-MSE analysis yet implicated in the same path-
ways. To avoid a technical bias resulting from the initial protein 
precipitation, this validation was performed on samples gen-
erated by an independent precipitation. Spearman correlation 
confirmed a positive relationship between predicted LC-MSE and 
SRM estimates for all measured samples (see Supplementary 
Figure S3). To exclude the possibility of a medication effect in 
our findings we correlated the fluphenazine mg equivalent with 
the measured SRM intensity estimates for each protein, but 
were unable to find any significant correlation (Spearman cor-
relation p > 0.05). The effects of other psychotropic medication 
(mood stabilizers and antidepressants) cannot be accounted for, 
as the respective dosages were not available and the samples 
and medication compliance at time of death does not allow 
extrapolation of the appropriate durations of treatment. SRM 
intensity estimates were also tested for correlation with further 
demographic characteristics (post-mortem interval, brain pH, 
age of death). However none of these variables showed signifi-
cant correlations (all Spearman correlation p > 0.05; for r and p 
values see Supplementary Table S5). SRM validation of the GO 
BP term glutamate secretion and the CC term clathrin-coated 
vesicle (a parent term of the various neurotransmitter vesicle 
membrane terms identified), both indicating presynaptic dis-
turbances, confirmed significantly elevated abundance levels in 
BD/CT (vesicular glutamate transporter 1 [VGLU1] FC 1.17, syn-
aptotagmin [SYT] FC 1.18, synaptophysin [SYPH] FC 1.13, and 
synapsin 1 [SYN1] FC 1.19) and MDD/CT (VGLU1 FC 1.19, SYT FC 
1.12, and SYN1 FC 1.14), while decreased levels were validated in 
SZ/CT (VGLU1 FC -1.12, SYT FC -1.13, SYPH FC -1.22, and SYN1 
FC -1.15) and MDD-P/MDD (VGLU1 FC -1.08, SYT FC -1.16, and 
SYN1 FC -1.16; see Figure 3 for overview and p values). A simi-
lar pattern, as indicated by GO and KEGG enrichment analysis, 
was replicated for glutamate catabolism with increased protein 
abundance levels in BD/CT (glutamate decarboxylase 2 FC 1.28 
and aspartate aminotransferase [AATM] FC 1.19) and MDD/CT 
(AATM FC 1.19) and decreased levels in SZ/CT (glutamate decar-
boxylase 2 FC -1.13 and AATM FC -1.07) and MDD-P/MDD (AATM 
FC -1.14). SRM validation of the GO BP terms glycolysis and res-
piratory electron transport chain and the KEGG term oxidative 
phosphorylation, all primary components of cellular energy 
metabolism, confirmed elevated abundance levels in BD/CT 
(mitochondrial pyruvate kinase FC 1.08, fructose-bisphosphate 
aldolase A FC 1.09, and cytochrome C FC 1.17, mitochondrial ATP 
synthase subunit beta FC 1.17]) and MDD/CT (mitochondrial 
pyruvate kinase FC 1.09, fructose-bisphosphate aldolase A  FC 
1.09, cytochrome C FC 1.09, and mitochondrial ATP synthase 
subunit beta FC 1.09), while decreased levels were validated in 
SZ/CT (cytochrome C FC -1.08 and mitochondrial ATP synthase 
Figure 1. (A–E) Volcano plots of group comparisons showing the adjusted significance p value (log2) versus fold change (log2). The plots show an increased magnitude 
of differential protein abundances in BD/CT, MDD/CT, and MDD-P/MDD compared to SZ/CT and MDD-P/CT. BD/CT and MDD/CT revealed a prominent trend towards 
increases in protein levels and decreases in the MDD-P/MDD comparison. Horizontal grey lines indicate an adjusted p value threshold of 0.05; vertical grey dotted lines 
indicate a fold change threshold of 10%. Red dots indicate positive fold changes; green dots indicate negative fold changes. (F) Correlation map identifying overlapping 
protein abundance patterns between diseases. Spearman correlation coefficents (p < 0.001) were estimated for the fold changes of all significantly-changed proteins 
overlapping between any two comparisons (see Supplementary Figure S1A–J). Positive correlations indicate fold change patterns in the same direction.
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subunit beta FC -1.10) and MDD-P/MDD (mitochondrial pyruvate 
kinase FC -1.10, fructose-bisphosphate aldolase A FC -1.10, and 
mitochondrial ATP synthase subunit beta FC -1.08).
Discussion
This comprehensive study is the first to combine non-hypoth-
esis–driven label-free LC-MSE with an enrichment analysis in 
post-mortem brains (anterior prefrontal cortex, BA10) from 
psychotic and affective disorder patients. We identified shared 
affected pathways across these major psychiatric disorders and 
validated them by targeted labeled SRM mass spectrometry 
analyses, a combination which has previously not been applied 
in neuropsychiatric research. This novel integrative approach 
delivers proof that systemic differences and commonalities 
exist within the psychoaffective disease spectrum, substantiat-
ing previous findings (for a review see van Os and Kapur, 2009).
Comparing the altered proteins and pathways and their 
inter-disease correlations, we identified molecular similari-
ties across all major neuropsychiatric disorders analyzed. Our 
results imply that pathological hallmarks of these disorders 
may derive from similar effects at the protein level affecting 
overlapping biological pathways. This supports the view that 
the pathologies of major neuropsychiatric disorders represent 
a disease spectrum. Integration of the quantitative proteomic 
and molecular pathways suggests that BD and MDD are most 
closely related, whereas the comparison between MDD and 
MDD-P showed alterations in similar pathways with opposite 
directional change. SZ appeared to be more distinct when com-
pared to affective disorders. Interestingly, pathways identified 
in affective psychosis (MDD-P/MDD) showed similar directional 
patterns as in the SZ/CT comparison, suggesting a common sig-
nature of psychotic features.
For all disease groups, overlapping GO biological pathway 
and cellular compartment annotations indicated alterations in 
presynaptic glutamatergic neurotransmission (glutamate secre-
tion; clathrin-sculpted glutamate transport vesicle membrane; 
and glutamate catabolism) and energy metabolism (respira-
tory electron transport chain; gluconeogenesis; carbohydrate 
catabolism; glycolysis; lipid catabolism; and ATP synthesis) as 
primary comparison nodes. This was further supported by a sec-
ond enrichment analysis based on KEGG pathway annotation 
(alanine, aspartate, and glutamate metabolism; oxidative phos-
phorylation; and metabolic pathways). Consequently, proteins 
for SRM validation were selected from these pathway categories 
to validate our findings. To expand the systemic scope of our 
Figure 2. Functional enrichment analysis of GO biological pathway, GO cellular compartment,and KEGG pathway annotations based on conditional hypergeometric 
testing of significantly changed proteins in the anterior prefrontal cortex of four different major psychiatric disorders. Only comparisons with significant enrichment in 
at least three different comparisons are displayed. The fold change bins resulting from the quantitative proteome comparison were separately analyzed for enrichment 
and subsequently clustered and ordered to render terms comparable if they were shared across disorders. Downregulations are depicted in green and upregulations 
are shown in red. Color-coded z-score–transformed p values indicate the significance of enrichment for every bin. Representative enriched GO terms are annotated. 
Pathways highlighted in yellow were chosen for SRM validation. For visual purposes the z-score scale and GO terms were truncated.
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functional network discoveries, this included the quantification 
of proteins implicated in the same biological pathways, which 
were not detected in the LC-MSE profiling analysis.
Our integrated analysis suggests decreased glutamater-
gic neurotransmission in SZ and affective psychosis, while an 
increase in the same domain was found in BD and MDD. This is 
consistent with the postulated importance of glutamate in the 
pathophysiology of psychotic states and is supported by previ-
ous findings which reported reduced glutamate metabolism in 
SZ patients in the frontal cortex and other brain regions (Tsai 
et  al., 1995) and findings of alterations in glutamate signal-
ing in transcriptomic (Tkachev et al., 2007) and genomic stud-
ies (Miyatake et al., 2002; Timms et al., 2013). Also, a decrease 
in medio-fronto-cortical glutamate levels has been confirmed 
in a meta-analysis investigating 166 SZ patients and 171 CTs 
(Marsman et al., 2013). The importance of glutamatergic signal-
ing has been demonstrated by pharmacological studies, which 
have shown that blocking glutamatergic signaling with the 
N-methyl-D-aspartate (NMDA)-receptor antagonists PCP (Luby 
et al., 1962) or ketamine (Adler et al., 1999) in healthy subjects 
induces a hypoglutamatergic psychosis-like state with cognitive 
disturbances and sensory dysfunctions indistinguishable from 
SZ (Umbricht et al., 2000). Additional support for the importance 
of glutamatergic neurotransmission in psychotic states comes 
from clinical studies evaluating NMDA-receptor agonists (e.g., 
glycine and D-serine) and glycine transporter inhibitors (e.g., 
sarcosine) in combination with typical and atypical antipsy-
chotics in SZ, resulting in marked improvements in negative 
and cognitive symptoms (Javitt, 2004).
Conversely, in BD and MDD release inhibition and recep-
tor blockade of the glutamatergic system has been shown to 
improve affective symptoms, providing clinical evidence for the 
glutamatergic hyperfunction of these disorders, as identified in 
our analysis. This dates back to the discovery of antidepressant 
effects of NMDA-receptor antagonism (Crane, 1961). Lamotrigine, 
a known inhibitor of glutamate signaling, ameliorates episodes 
of persistent or treatment-resistant depression in BD (Berk, 
1999; Boylan et al., 2002), as does ketamine (Diazgranados et al., 
2010). Furthermore, an inhibitor of glutamate release, riluzole 
(Lamanauskas and Nistri, 2008), which has been shown to be 
effective in treatment-resistant MDD (Zarate et  al., 2004), has 
also demonstrated efficacy in BD (Zarate et al., 2005). In addi-
tion, single doses of ketamine also show a rapid antidepres-
sant effect in treatment-resistant cases (Berman et  al., 2000; 
Krystal et al., 2002; Zarate et al., 2006). Recently, these findings 
were followed up by the successful evaluation of lanicemine, a 
low-trapping NMDA-receptor antagonist suitable for long-term 
treatment without the dissociative and psychotomimetic side 
Figure 3. Multivariate analysis of SRM estimates as shown by condition plots illustrating the systemic difference between the disorders. X-axis is condition and y-axis 
is log ratio of endogenous (L = light) over reference (H = heavy). Dots represent the mean of log2 ratio for each condition and error bars indicate the confidence interval 
with 0.95 significance. The interval is not related with model-based analysis. Significant changes, as measured by LC-MSE, are indicated below each protein. SRM was 
able to validate abundance changes in GO term associated proteins as suggested by LC-MSE analysis. Corrected p values (p*) were determined by post hoc correction 
after Benjamini Hochberg.
D
ow
nloaded from
 https://academ
ic.oup.com
/ijnp/article-abstract/18/2/pyu019/690311 by Erasm
us U
niversiteit R
otterdam
 user on 19 June 2019
8 | International Journal of Neuropsychopharmacology, 2015
effects of ketamine (Sanacora et al., 2013). Further evidence for 
increased levels of glutamate in the frontal cortex of mood dis-
order patients is provided by proton magnetic resonance spec-
troscopy studies (Gigante et al., 2012) in living patients, as well 
as in post-mortem brain tissue (Hashimoto et  al., 2007) and 
in serum (Kim et  al., 1982) and plasma (Altamura et  al., 1993; 
Hoekstra et al., 2006).
Our results implicate a presynaptic dysfunction in the frontal 
cortex of all investigated disorders, as indicated by the cellular 
compartment annotation in the enrichment analysis. This was 
validated by SRM mass spectrometry analyses, which showed 
changes in a number of presynaptic vesicle proteins (synap-
sin 1 SYN1, synaptotagmin 1 SYT1, and synaptophysin SYP). 
Furthermore, we were able to show that altered glutamatergic 
signaling (glutamate secretion) across all comparisons might be 
due to glutamate release abnormalities by measuring the abun-
dance of a bottleneck protein for this GO term, the vesicular 
glutamate transporter 1 (Daniels et al., 2006). This implies that 
our pathway analysis can be expanded beyond the pool of pro-
teins identified by the LC-MSE profiling experiments. Increased 
vesicular glutamate transporter 1 expression has been linked 
to mood disorders (Eastwood and Harrison, 2010), and novel 
compounds inhibiting the crucial step of vesicle loading are cur-
rently being evaluated for their potential efficacy for treatment 
of affective disorders (Thompson et al., 2005).
Glutamate is the most abundant excitatory neurotransmit-
ter in the brain and a key component of intermediary energy 
metabolism (Erecinska and Silver, 1990). Approximately two 
thirds of the energy derived from brain glucose metabolism 
is invested into glutamatergic neurotransmission and related 
events (Shulman et  al., 2002). This link between synaptic 
transmission and glutamate release with glycolysis and ATP 
biosynthesis is consistent with the second major outcome of 
our pathway enrichment analysis. Besides the presynaptic 
glutamatergic abnormalities, we detected a dysregulation of 
the glutamate catabolism, which is interconnected with the 
energy metabolism found to be dysregulated across all inves-
tigated disorders. This finding was validated by SRM (gly-
colysis; respiratory electron transport chain; and oxidative 
phosphorylation). The detected abnormalities follow a simi-
lar fold-change directional pattern to those observed for the 
presynaptic glutamatergic neurotransmission. The relevance 
of this finding has been demonstrated in a clinical study, in 
which rapid antidepressant response to ketamine was linked 
to increased pre-treatment fronto-cortical metabolic activ-
ity during exposure to negative emotional stimuli (Salvadore 
et al., 2009).
In vivo neuroimaging studies have already demonstrated 
reduced frontal ATP levels (Volz et al., 2000) and metabolic rates 
in SZ patients (Ingvar and Franzen, 1974; Buchsbaum et  al., 
1984). Additionally, MDD patients with psychotic features were 
found to display reduced prefrontal activation during cogni-
tive encoding tasks compared to CTs (Kelley et al., 2013), while 
the ameliorating effects of electroconvulsive therapy in psy-
chotic depression patients were correlated with an increase in 
fronto-cortical metabolism (McCormick et  al., 2007). This sup-
ports our findings of a hypofunction of energy metabolism in 
SZ and affective psychosis. Previous targeted SZ post-mortem 
brain studies have identified reduced transcript and protein lev-
els (Cavelier et al., 1995; Bubber et al., 2011), along with reduced 
activity (Maurer et al., 2001) of the mitochondrial electron trans-
port chain, further supported by the results of several prot-
eomic (Beasley et al., 2006; Clark et al., 2006) and transcriptomic 
(Prabakaran et al., 2004) studies.
Consistent with our proteomic findings of increased energy 
metabolism in BD, previous studies reported elevated fronto-
cortical markers of metabolism in medication-free BD patients 
(Kato et  al., 1998; Dager et  al., 2004), increased frontal activ-
ity in patients undergoing a manic episode (Blumberg et  al., 
2000), and a raised metabolism of glucose in the frontal lobe 
of treatment-resistant mildly depressed and euthymic BD 
patients (Ketter et al., 2001). Similar signs of increased energy 
metabolism (Gruber et  al., 2003) have also been reported for 
MDD, in line with our proteomic and bioinformatic findings. 
Higher prefrontal metabolism in MDD patients has been 
shown to be normalized by several antidepressant drug classes 
(Drevets et  al., 1992) and psychotherapy (Brody et  al., 2001; 
Kennedy et  al., 2007), providing in vivo proof for a prefrontal 
hypermetabolic state.
In terms of a systems biological perspective, this study pro-
vides evidence that abnormalities in energy metabolism are 
secondary effects of presynaptic abnormalities in glutamatergic 
neurotransmission. This is the first global and systemic prot-
eomic approach which has provided molecular evidence for a 
hyperglutamatergic state in affective disorders and a hypo-
glutamatergic state in psychosis, associated with increased or 
decreased brain energy metabolism, respectively. Although we 
aimed to exclude methodological biases by carrying out inde-
pendent protein extraction for the SRM validation phase, fur-
ther validation using extracts from independent sample sets is 
still required. Our results provide evidence for the potential of 
drug interventions specifically focusing on glutamatergic neu-
rotransmission counteracting these dysregulations. These find-
ings also encourage the re-conceptualization of the psychiatric 
classification system supported by characteristic disease-spe-
cific pathological hallmarks, if similar distinctive signatures for 
affective and psychotic traits can be validated in larger patient 
cohorts by in vivo measurements. The presented enrichment 
analysis offers a comparative insight in the spectrum of major 
neuropsychiatric disorders while suggesting candidate path-
ways for future investigations to evaluate their diagnostic and 
therapeutic potential.
Supplementary Material
For supplementary material accompanying this paper, visit 
http://www.ijnp.oxfordjournals.org/
Supplementary Figure S1 (a-j): Correlation of log2 protein 
fold changes between all possible disease comparisons across 
all proteins. Spearman correlation for all proteins significantly 
changed in both given comparisons. Coloured dots indicate fold 
change directions in both comparisons: green=both negative; 
red=both positive; grey=opposite directions. Vertically and hori-
zontally dotted lines indicate a fold change threshold of 10%. 
Uniprot identifiers are given for selected protein fold changes of 
higher magnitude for a given comparison.
Supplementary Figure S2: Venn diagram displaying the over-
lap of significantly changed proteins across all comparisons.
Supplementary Figure S3: Spearman correlation of predicted, 
normalized SRM and LC-MSE estimates.
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